CYP2C9 and Hypoglycemia: As reviewed recently [50], with all the sulfonylureas, there is risk of hypoglycaemia if plasma drug concentrations are not maintained within the normal therapeutic range, and low CYP2C9 activity due to enzyme inhibition or genetic polymorphism may increase this risk.